Last update Aug. 6, 2017

C40H50N8O6

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Usually used alone or in combination with sofosbuvir in the treatment of hepatitis C.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (high molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into breast milk, so that, although there is disagreement (Thompson 2016), some authors consider that treatment with Daclatasvir, alone or in combination with sofosbuvir is not contraindicated during breastfeeding (Spera 2016, LactMed 2016).


See below the information of these related products:

  • Maternal Hepatitis C Infection (Safe product and/or breastfeeding is the best option.)
  • Sofosbuvir (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for C40H50N8O6 .

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C40H50N8O6 is Daclatasvir in Molecular formula.

Is written in other languages:

Group

C40H50N8O6 belongs to this group or family:

Tradenames

Main tradenames from several countries containing C40H50N8O6 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 67 %
Molecular weight 739 daltons
Protein Binding 99 %
VD 0.66 l/Kg
Tmax 1 - 2 hours
T½ 12 - 15 hours

References

  1. Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet. 2019 Oct;58(10):1237-1263. Abstract
  2. EMA. Daclatasvir. Ficha técnica. 2017 Full text (in our servers)
  3. EMA. Daclatasvir. Drug Summary. 2017 Full text (in our servers)
  4. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016 Abstract Full text (link to original source) Full text (in our servers)
  5. Spera AM, Eldin TK, Tosone G, Orlando R. Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women? World J Hepatol. 2016 Abstract Full text (link to original source) Full text (in our servers)
  6. LactMed. Daclatasvir. Full Record Display. 2016 Full text (in our servers)

Total visits

1,587

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM